
Efficient Dlx2-mediated astrocyte-to-neuron conversion and inhibition of neuroinflammation by NeuroD1
简介:
- 作者: Min-Hui Liu, Yu-Ge Xu, Xiao-Ni Bai, Jian-Hua Lin, Zong-Qin Xiang, Tao Wang, Liang Xu, Wen Li, Gong Chen
- 杂志: BioRxiv
- Doi: https://www.doi.org/10.1101/2022.07
- 出版日期: 2022 Jul 12
论文中使用的产品/服务
Quotation shows PackGene:hGFAP promoter used in the AAV vectors is the synthetic 681- bp gfaABC1D. The construction of pAAV GFAP::GFP, GFAP::Dlx2-P2A-GFP, GFAP::NeuroD1-P2A-GFP, the following AAV9 virus package, purification with iodixanol and subsequent concentration, as well as virus titration were produced by PackGene® Biotech, LLC (Guangzhou, China).
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:Both adult male and female wild-type C57BL/6J mice (Guangdong Medical Laboratory Animal Center) and Aldh1l1::CreERT2 transgenic mice (The Jackson Laboratory, RRID:IMSR_JAX:031008) at 2-5 months of age were recruited in the experiments.
摘要
In vivo astrocyte-to-neuron (AtN) conversion induced by overexpression of neural transcriptional factors has great potential for neural regeneration and repair. Here, we demonstrate that a single neural transcriptional factor Dlx2 converts mouse striatal astrocytes into neurons in a dose-dependent manner. Lineage-tracing studies in Aldh1l1-CreERT2 mice confirm that Dlx2 can convert striatal astrocytes into DARPP32+ and Ctip2+ medium spiny neurons (MSNs). Time-course studies reveal a gradual conversion from astrocytes to neurons in 1 month, with a distinct intermediate state in-between astrocytes and neurons. Interestingly, when Dlx2-infected astrocytes start to lose astrocytic markers, the other local astrocytes proliferate to maintain astrocytic level in the converted areas. Unexpectedly, while Dlx2 efficiently reprograms astrocytes into neurons in the grey matter striatum, it also induces partial reprogramming of astrocytes in the white matter corpus callosum. Such partial reprogramming of white matter astrocytes is associated with neuroinflammation, which can be essentially suppressed by the addition of NeuroD1. Our results highlight the importance of investigating AtN conversion both in the grey matter and white matter in order to thoroughly evaluate therapeutic potentials. This study also unveils a critical role of anti-inflammation by NeuroD1 during AtN conversion.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
